Batroc
Then you are assuming that:
- there will be no farm-in type deal announced for the hugely valuable HU91 and follow on antibody trial.
- Quest diagnostics will dump it's internal proteomic programs and purchase NSCLC tests from competitors next year (just as its own test is cleared for market).
- Currently strong Evolis sales will collapse;
- AIM trials next year will fail;
- Indicative results from the Japanese MK Elisa trials will turn from positive to negative;
- There is no actual demand found for a better Mesothelioma diagonstic test;
- The positive reported results MK antibodies have had in treating bone cancer were just a case of academic fraud;
- US research and diagnostic houses (such as Quest) are not actually purchasing MK Elisas for further evaluation;
- The FDA will fail to attend a scheduled meeting with CDY and several reseach and diagnostics companies;
- CX bladder will not become a gold standard bencmark to be followed.
- The dozen or so companies in consultation with Maria will leave King Street unimpressed;
I can't say that any or all of these failures won't happen. But nor can anyone say that they will.
cheers
- Forums
- ASX - By Stock
- cap raising
BatrocThen you are assuming that:- there will be no farm-in type...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
First paediatric clinical site activated – major recruitment milestone and key appointment announced
NEWS
Biotech innovator secures $5.5M R&D tax incentive refund – major boost for cutting-edge programs
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable